The American Society of Clinical Oncology Annual Meeting, 2015

Stakeholder Definition of Value in Cancer: Where Are We 1 Year Later?

July 15, 2015

Evidence-Based Oncology

A very popular session on the "value" of cancer care during the annual meeting of the American Society of Clinical Oncology (ASCO) brought together a patient representative, an oncologist, an ASCO representative, and a payer.

New Oncology Clinical Trial Designs: What Works and What Doesn't?

July 10, 2015

Evidence-Based Oncology

Basket and umbrella studies as well as adaptive enrichment design strategies represent novel approaches to testing targeted therapeutics in oncology, and a session at ASCO's annual meeting discussed the nuts and bolts of these design strategies.

Largest-Ever Precision Medicine Oncology Trial Ready for Launch

July 10, 2015

Evidence-Based Oncology

A landmark clinical trial that will channel patients into treatment arms based on molecular abnormalities rather than cancer type aims to simultaneously test the efficacy of more than 20 drugs.

Will Specialty Oncology Products Follow the Sovaldi Way?

July 13, 2015

Evidence-Based Oncology

The American Journal of Managed Care invited healthcare experts to discuss the challenges associated with managing and paying for newer and more expensive agents in oncology, during the Oncology Stakeholders Summit.

Phase 3 RECOURSE Trial Holds Promise for Colorectal Cancer

July 13, 2015

Evidence-Based Oncology

A poster presented at the 2015 annual meeting of the American Society of Clinical Oncology shared encouraging phase 3 survival data from the RECOURSE trial, after evaluating specific geographic subgroups.

Oncologists Inspect the Costs and Quality of Cancer Care

July 15, 2015

Evidence-Based Oncology

During the session "Health Services Research and Quality of Care" at the annual meeting of the American Society of Clinical Oncology, oncologists discussed factors that influence clinical trial participation and the cost of cancer care.

Novel Options in Melanoma and Multiple Myeloma

July 16, 2015

Evidence-Based Oncology

Immuno-oncology continues to deliver results in oncology, as seen from results presented at the annual meeting of the American Society of Clinical Oncology. The combination of nivolumab and ipilimumab significantly improved survival in melanoma, while elotozumab showed encouraging results in relapsed refractory multiple myeloma.

Choosing the Ideal Lymphoma Regimens

July 16, 2015

Evidence-Based Oncology

At the annual meeting of the American Society of Clinical Oncology in Chicago, physicians introduced some new lymphoma treatments as they described their personal experience with using them during the session, "Incorporating Novel Agents Into Lymphoma Therapy: Value in Everyday Practice."

Elotuzumab Combo Delays Myeloma Progression in Phase 3 Trial

July 16, 2015

Evidence-Based Oncology

A presscast held prior to the annual meeting of the American Society of Clincal Oncology presented interim results from the phase 3 ELOQUENT-2 trial. Adding elotuzumab to lenalidomide and dexamethasone reduced the risk of disease progression by 30% in patients with relapsed-refractory multiple myeloma.

Predictive Biomarkers Present Promise in Immuno-Oncology

July 16, 2015

Evidence-Based Oncology

A late-breaking abstract session early at the annual meeting of the American Society of Clinical Oncology presented datd for nivolumab in the treatment of hepatocellular carcinoma, non-squamous cell non-small cell lung cancer, and for tumors harboring mismatch repair deficiency.